tozorakimab

News

FDA starts review of AZ's COPD blockbuster hope

The FDA has started a priority review of AstraZeneca's first-in-class IL-33 inhibitor tozorakimab for COPD, setting up a decision in Q1 of 2027.

News

AZ is three for three with COPD hope tozorakimab

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

FDA starts review of AZ's COPD blockbuster hope

AZ is three for three with COPD hope tozorakimab

Where others missed, AZ's IL-33 drug hits the mark in COPD

argenx's Forte acquisition delivers coeliac trial win

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks